Home » Healthcare » Africa Human Insulin Market

Africa Human Insulin Market

Africa Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Africa Human Insulin Market Size 2023	USD 383.25 million
Africa Human Insulin Market, CGR	0.83%
Africa Human Insulin Market Size 2032	USD 415.07 million

Market Overview

Africa Human Insulin market size was valued at USD 383.25 million in 2023 and is anticipated to reach USD 415.07 million by 2032, at a CAGR of 0.83% during the forecast period (2023-2032).

The growth of the Africa Human Insulin market is primarily driven by the rising prevalence of diabetes across the continent, fueled by urbanization, lifestyle changes, and an aging population. Increasing healthcare awareness, along with government initiatives to improve access to diabetes care, further supports market growth. Additionally, advancements in insulin production technologies, including biosimilars and improved delivery systems, are enhancing treatment options. The growing focus on affordable healthcare solutions and expanding insurance coverage are also significant contributors to the market’s expansion. Moreover, partnerships between international insulin manufacturers and local distributors are improving availability in remote regions. Trends such as the rising adoption of digital health tools for diabetes management, including glucose monitoring systems and mobile apps, are expected to drive future demand for insulin. These factors, combined with a steady rise in healthcare investments, present a promising outlook for the market throughout the forecast period.

Geographically, the African human insulin market is diverse, with varying levels of healthcare access and diabetes prevalence across different regions. North Africa, including countries like Egypt, Algeria, and Morocco, has relatively better healthcare infrastructure, which supports a growing demand for insulin. In contrast, sub-Saharan Africa faces more challenges in terms of access to treatment, especially in rural areas where healthcare systems are underdeveloped. Key players in the African human insulin market include global pharmaceutical giants such as Novo Nordisk, Eli Lilly, and Pfizer, which dominate in terms of insulin supply. Local manufacturers like Biocon and Wockhardt are also making their presence felt, particularly in countries like India, which have expanded into African markets. These companies are crucial for increasing insulin availability and affordability, with many focusing on localized production or partnerships to overcome logistical barriers in distribution across the continent.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Africa human insulin market was valued at USD 383.25 million in 2023 and is expected to reach USD 415.07 million by 2032, growing at a CAGR of 0.83% during the forecast period (2023-2032).

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.

Increasing prevalence of diabetes across Africa, driven by lifestyle changes, urbanization, and rising obesity rates, is a key driver of the insulin market.
Market trends indicate growing adoption of insulin pens and syringes, with a shift toward more convenient and accurate delivery methods.
The competitive landscape includes major players like Novo Nordisk, Eli Lilly, and Biocon, alongside local manufacturers aiming to reduce import dependency.
High insulin prices and limited healthcare infrastructure in rural regions are major market restraints affecting accessibility.
North Africa, particularly Egypt and Algeria, leads the market, while sub-Saharan Africa is showing significant growth potential despite infrastructure challenges.
Local production initiatives and government policies aimed at improving healthcare access are expected to drive future market expansion.

Report Scope

This report segments the Africa Human Insulin Market as follows:

Market Drivers

Increasing Prevalence of Diabetes

One of the primary drivers of the Africa Human Insulin market is the rapidly increasing prevalence of diabetes across the continent. For instance, the World Health Organization (WHO) estimates that 54 million adults in Africa had diabetes in 2022, with more than half of them undiagnosed and untreated. As urbanization accelerates, more individuals are adopting sedentary lifestyles, which often leads to poor dietary habits and a higher risk of developing Type 2 diabetes. Additionally, the growing aging population in Africa contributes to an increase in chronic diseases, including diabetes. According to the World Health Organization (WHO), the number of adults with diabetes is expected to rise significantly in the coming years, which is driving demand for insulin therapies. The increasing incidence of diabetes creates a substantial need for insulin treatments, propelling market growth as more people require access to affordable and effective diabetes management options.

Government Initiatives and Healthcare Improvements

Governments across Africa are recognizing the need to address chronic health issues, particularly diabetes, and are implementing various initiatives to improve access to healthcare and medications. For instance, the WHO launched the Global Diabetes Compact, an initiative aimed at improving diabetes prevention, diagnosis, and treatment while ensuring equitable access to essential care and medicines. Many African nations are focusing on expanding healthcare infrastructure and enhancing their healthcare systems, which directly influences the demand for insulin. National programs aimed at tackling non-communicable diseases, including diabetes, are becoming more common, and public health campaigns are raising awareness about the condition. In parallel, several governments are taking steps to improve access to essential medicines through regulatory reforms and increased investment in healthcare. These efforts are helping to make insulin more accessible, affordable, and available to a wider population, driving market growth.

Advancements in Insulin Production and Delivery Technologies

Technological advancements in insulin production and delivery systems are also fueling the growth of the Africa Human Insulin market. Innovations such as biosimilar insulin, which provides a more affordable alternative to branded insulin, are gaining traction across the continent. Biosimilars are helping to reduce the overall cost of insulin, making it more accessible to low- and middle-income populations. Moreover, improvements in insulin delivery methods, such as insulin pens, pumps, and smart devices, are contributing to better patient compliance and outcomes. These advancements are expanding treatment options for people with diabetes, which is driving demand for insulin. As technology continues to evolve, it is expected that even more efficient and patient-friendly insulin delivery systems will emerge, further stimulating market growth.

Growing Focus on Diabetes Awareness and Digital Health Tools

Increased awareness of diabetes and the rising adoption of digital health tools are shaping the future of insulin use in Africa. Public and private health organizations are focusing on educating the population about diabetes prevention, early diagnosis, and management, which is leading to higher demand for insulin. Moreover, the growing penetration of smartphones and mobile applications in Africa is facilitating the adoption of digital health tools, including glucose monitoring systems and diabetes management apps. These tools enable better self-management of the disease, which, in turn, increases the demand for insulin as part of a comprehensive diabetes management plan. The shift towards digital health solutions in Africa is creating new opportunities for insulin manufacturers to reach a wider audience and offer integrated care solutions, which will continue to boost market growth.

Market Trends

Increased Integration of Digital Health Tools

Digital health tools, including mobile apps for glucose monitoring, diabetes management, and insulin dose tracking, are gaining significant traction in Africa. For instance, the Africa digital health market is projected to grow significantly due to the increasing need for remote healthcare solutions. These tools are becoming increasingly important in helping patients manage their diabetes effectively, and their integration with insulin therapies is expected to grow. With the widespread use of smartphones across the continent, mobile health solutions are becoming more accessible, allowing for better tracking of blood sugar levels and insulin administration. The rise of digital platforms that offer personalized diabetes management is driving increased demand for insulin, as these solutions emphasize continuous monitoring and adherence to insulin regimens. The growth of telemedicine and online consultations further complements this trend by providing patients with remote access to healthcare services and support.

Focus on Preventative Healthcare and Public Awareness Campaigns

In addition to the increasing availability of insulin, there is a notable trend towards preventative healthcare and greater public awareness of diabetes in Africa. For instance, the World Health Organization (WHO) has highlighted barriers to insulin availability and is working on initiatives to promote universal access. Governments and non-governmental organizations are working to raise awareness about diabetes prevention, early diagnosis, and the importance of regular insulin treatment. Health campaigns that focus on healthy lifestyles, nutrition, and exercise are becoming more common, helping to reduce the number of new diabetes cases. Simultaneously, educational programs about insulin and diabetes management are encouraging patients to seek timely treatment, leading to a higher demand for insulin therapies. As more people become aware of the risks of diabetes and the benefits of early intervention, the market for human insulin will continue to expand.

Rising Demand for Biosimilars and Affordable Insulin Options

A prominent trend in the Africa Human Insulin market is the growing demand for biosimilars, which provide an affordable alternative to branded insulin products. As many African countries face budget constraints, the need for cost-effective insulin solutions is more pressing than ever. Biosimilars, which are highly similar to original biologic insulin products, offer a viable solution for reducing healthcare costs without compromising on efficacy. Their availability is expanding, driven by local production initiatives and the growing acceptance of biosimilars among healthcare providers and patients. This trend is expected to continue as countries focus on improving access to insulin for a broader population, contributing to the overall growth of the market.

Expansion of Insulin Delivery Devices

The trend towards more efficient insulin delivery systems is another key factor shaping the Africa Human Insulin market. Traditional syringe-based delivery methods are being increasingly replaced by insulin pens, pumps, and other advanced devices that enhance patient comfort, accuracy, and compliance. These systems are becoming more widespread in African countries, driven by improvements in healthcare infrastructure and greater availability of technology. The use of insulin pens and pumps, which offer greater convenience and precision, is improving treatment outcomes, particularly for people with Type 1 diabetes. As more patients adopt these devices, the demand for insulin is expected to rise, fueling the market’s expansion.

Market Challenges Analysis

Limited Access to Healthcare Infrastructure

One of the significant challenges facing the Africa Human Insulin market is the limited access to healthcare infrastructure, particularly in rural and underserved areas. For instance, a WHO report highlights that high prices, low availability of human insulin, and weak health systems are among the main barriers to universal access to insulin. Poor transportation networks, insufficient cold chain storage for insulin, and unreliable supply chains further complicate the distribution of insulin to remote areas. These challenges result in irregular insulin availability and compromised patient care, leading to difficulties in managing diabetes effectively. Overcoming these infrastructure barriers requires significant investment in healthcare systems and logistics to ensure that insulin reaches all segments of the population, including those in rural and low-income areas.

High Cost of Insulin and Economic Barriers

Another major challenge is the high cost of insulin, which remains prohibitive for a significant portion of the African population, particularly in lower-income countries. While efforts to introduce biosimilars and lower-cost insulin options are underway, many patients still struggle with affordability due to limited healthcare coverage and out-of-pocket expenses. The lack of universal health insurance in many African nations further exacerbates this issue, as many individuals with diabetes must pay for their insulin treatment out-of-pocket. Consequently, a large number of patients may forgo necessary treatment or resort to suboptimal care, leading to higher rates of complications and hospitalizations. To address these challenges, governments, insurers, and pharmaceutical companies need to collaborate to find sustainable solutions that make insulin more affordable and accessible to all populations.

Market Opportunities

The market for human insulin in Africa presents a significant opportunity for growth due to the increasing prevalence of diabetes across the continent. According to the International Diabetes Federation (IDF), Africa has witnessed a sharp rise in the number of diabetes cases, with millions of people diagnosed annually. This surge, combined with a rising middle class and improvements in healthcare infrastructure, provides a substantial market for both affordable and high-quality insulin. As healthcare access improves, the demand for insulin is expected to grow, particularly in emerging economies where diabetes is often underdiagnosed and untreated. This growing need presents a compelling opportunity for both local and international companies to enter the market, focusing on the affordability, availability, and accessibility of human insulin.

Furthermore, there is a significant potential for innovation and partnerships within the African healthcare ecosystem to address the challenges posed by diabetes care. Local production of insulin or strategic partnerships with multinational pharmaceutical companies can help reduce dependency on imports and drive down costs. This, in turn, will facilitate broader access to life-saving treatment in regions with limited healthcare resources. The increasing awareness around diabetes management, along with the support from African governments and international health organizations, creates an encouraging environment for the expansion of the human insulin market. The opportunity lies in the development of cost-effective solutions and distribution models tailored to the unique needs of the African population, ensuring that insulin reaches those who need it most.

Market Segmentation Analysis:

By Device:

The human insulin market in Africa is segmented by device types, with major categories including pens, syringes, and others. Insulin pens are witnessing significant demand due to their convenience, ease of use, and ability to provide accurate dosing. These pens are becoming increasingly popular in urban areas and among patients who prefer more discreet and efficient methods of insulin administration. Syringes, on the other hand, remain a widely used option, particularly in rural regions, where affordability and accessibility are key factors. Syringes are cost-effective and have a long-standing presence in the market, making them a preferred choice for many individuals, especially those with lower income levels. Other devices, such as insulin pumps and inhalers, are also gaining traction but remain limited in penetration due to high costs and limited availability. However, with increasing healthcare access and the potential for local manufacturing, the demand for these devices is expected to rise gradually, especially in more developed healthcare environments.

By Indication:

The human insulin market in Africa is further segmented by indication, with three primary categories: Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes, a chronic condition that requires lifelong insulin therapy, holds a significant market share, especially among the younger population. Although the prevalence of Type 1 diabetes is lower than Type 2, the need for consistent insulin treatment drives demand in specialized healthcare settings. Type 2 diabetes, the more common form of the disease, represents the largest market segment in Africa, fueled by lifestyle changes, urbanization, and rising obesity rates. This segment demands insulin therapy, particularly in late stages of the disease. Gestational diabetes, though less common, is on the rise as a result of changing dietary habits and an increase in maternal age. While this segment remains a smaller part of the market, the need for insulin during pregnancy presents opportunities for targeted therapies and treatment programs in maternity and healthcare clinics.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Egypt
Nigeria
Algeria
Morocco
Rest of Africa

Regional Analysis

Egypt

Egypt holds a significant share of the African human insulin market, contributing approximately 18% of the total market value. This is primarily driven by the country’s large population and the high prevalence of diabetes, with an increasing number of individuals diagnosed each year. The Egyptian government has made strides in improving healthcare infrastructure and access to treatment, particularly in urban areas, where the demand for insulin is robust. The demand is further bolstered by a growing middle class and greater awareness of diabetes management. Despite challenges such as high healthcare costs and a reliance on imported insulin, Egypt remains a key player in the region, with the market expected to grow due to both increased access to healthcare and the potential for local insulin production.

Nigeria

Nigeria is another major market for human insulin in Africa, accounting for approximately 20% of the market share. As Africa’s most populous country, Nigeria faces a significant challenge with the rising prevalence of diabetes, particularly Type 2 diabetes, driven by urbanization, changing lifestyles, and increased obesity rates. The demand for insulin in Nigeria is also rising due to a growing awareness of diabetes and an expanding middle class seeking more advanced treatment options. However, Nigeria’s healthcare system faces challenges such as inadequate infrastructure, limited access to insulin in rural areas, and a reliance on imported products, which drives up costs. Nevertheless, Nigeria remains a key market for insulin, with prospects for growth as healthcare access improves and more affordable solutions are introduced.

Algeria

Algeria, accounting for around 12% of Africa’s human insulin market, represents a growing market for insulin due to the country’s increasing diabetes prevalence and improving healthcare system. The rise in Type 2 diabetes cases, driven by lifestyle factors, is a major contributor to the demand for insulin in Algeria. The government has made significant investments in healthcare infrastructure, which is facilitating better access to insulin across the population. While Algeria still faces challenges with ensuring insulin availability in rural regions, the market is poised for growth as more patients gain access to modern treatment options. Local production of insulin is also a potential avenue for reducing costs and improving access to insulin in Algeria, making it an attractive market for both local and international players.

Morocco and Rest of Africa

Morocco, with approximately 10% of the market share, is another growing hub for human insulin in Africa. The country’s improving healthcare system, higher rates of urbanization, and an increase in diabetes awareness contribute to a steady demand for insulin. The Moroccan market is increasingly open to innovative healthcare solutions and new treatment options, which will likely fuel growth in the coming years. However, challenges related to cost and accessibility remain and The “Rest of Africa” region, which accounts for roughly 40% of the market share, includes various nations across sub-Saharan Africa, where the insulin market is diverse and fragmented. In many of these countries, diabetes awareness and treatment access are limited, but rapid urbanization, population growth, and international health initiatives are expected to drive future market expansion. The variability in healthcare infrastructure across different nations presents both challenges and opportunities, making it a region with significant untapped potential for the human insulin market.

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company

Competitive Analysis

The Africa human insulin market is highly competitive, with several leading global and regional players actively involved in the supply of insulin. Major international players such as Novo Nordisk, Eli Lilly, Pfizer, and MannKind Corporation dominate the market, leveraging their strong brand presence and vast distribution networks. These companies offer a wide range of insulin products, including rapid-acting, long-acting, and premixed insulins, catering to different diabetes care needs. These players leverage strong brand recognition, extensive distribution networks, and advanced research and development capabilities to maintain a competitive edge. Many of these companies have also invested in partnerships with local distributors or healthcare providers to enhance product availability across the continent. Regional companies, on the other hand, are increasingly making their presence felt by focusing on cost-effective insulin solutions tailored to the African market. These players often emphasize affordability and accessibility, addressing the high price sensitivity in the region. Local production initiatives, as well as collaborations with governments and NGOs, are common strategies for regional players to overcome distribution challenges and regulatory hurdles. As the demand for insulin grows in Africa, the competition between global and regional companies is expected to intensify, particularly as market players seek to improve the accessibility and affordability of diabetes care. This dynamic will likely lead to enhanced product offerings, more localized production, and wider distribution networks across the continent.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The market concentration of human insulin in Africa remains moderate, with a few global leaders holding a dominant share, alongside a growing number of regional and local players. The market is characterized by high competition between well-established multinational pharmaceutical companies and emerging local manufacturers aiming to meet the increasing demand for insulin. While global players benefit from strong brand recognition, advanced R&D, and large-scale production, regional players focus on providing cost-effective alternatives and improving accessibility, particularly in underserved areas. The market’s characteristics include a reliance on both imported and locally produced insulin, with the latter gaining traction as governments and private sectors push for local manufacturing to reduce costs and dependency on imports. The increasing prevalence of diabetes, combined with rising awareness and healthcare improvements, is driving growth in the market. However, challenges such as high product costs, distribution barriers, and limited healthcare infrastructure persist in several regions.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The demand for human insulin in Africa is expected to grow steadily due to the rising prevalence of diabetes.
Local manufacturing initiatives are likely to expand, reducing dependency on imports and improving affordability.
Technological advancements in insulin delivery devices will enhance treatment convenience and patient adherence.
Public and private sector partnerships will play a key role in improving insulin accessibility across rural and underserved areas.
Healthcare infrastructure development across various African regions will support broader distribution of insulin products.
Awareness campaigns and early diagnosis efforts will increase the number of diagnosed and treated diabetes patients.
Regulatory reforms are anticipated to streamline approval processes and encourage market entry of affordable insulin.
Investment in cold chain logistics and supply chain improvements will enhance product availability and stability.
Competitive pricing strategies among manufacturers will drive down costs and expand market reach.
Government support and international aid programs will continue to strengthen diabetes care and insulin accessibility.

CHAPTER NO. 1 : INTRODUCTION 24

1.1.1. Report Description 24

Purpose of the Report 24

USP & Key Offerings 24

1.1.2. Key Benefits for Stakeholders 24

1.1.3. Target Audience 25

1.1.4. Report Scope 25

1.1.5. Regional Scope 26

CHAPTER NO. 2 : EXECUTIVE SUMMARY 27

2.1. Human Insulin Market Snapshot 27

2.1.1. Africa Human Insulin Market, 2018 – 2032 (USD Million) 28

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 29

3.1. Russia-Ukraine and Israel-Palestine War Impacts 29

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 30

4.1. Introduction 30

4.2. Market Drivers 31

4.2.1. Driving Factor 1 Analysis 31

4.2.2. Driving Factor 2 Analysis 32

4.3. Market Restraints 33

4.3.1. Restraining Factor Analysis 33

4.4. Market Opportunities 34

4.4.1. Market Opportunity Analysis 34

4.5. Porter’s Five Forces Analysis 35

4.6. Value Chain Analysis 36

4.7. Buying Criteria 37

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 38

5.1. Import Analysis by Region 38

5.1.1. Africa Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 38

5.2. Export Analysis by Region 39

5.2.1. Africa Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 39

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 40

6.1. Demand Analysis by Region 40

6.1.1. Africa Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 40

6.2. Supply Analysis by Region 41

6.2.1. Africa Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 41

CHAPTER NO. 7 : PRODUCTION ANALYSIS 42

7.1. Production Analysis by Region 42

7.1.1. Africa Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 42

CHAPTER NO. 8 : PRICE ANALYSIS 43

8.1. Price Analysis by Region 43

8.1.1. Africa Human Insulin Market Price, By Region, 2018 – 2023 43

8.1.2. Africa Device Market Price, By Region, 2018 – 2023 43

8.2. Price Analysis by Device 44

8.2.1. Africa Human Insulin Market Price, By Device, 2018 – 2023 44

8.2.2. Africa Device Market Price, By Device, 2018 – 2023 44

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 45

9.1. Key Raw Materials and Suppliers 45

9.2. Key Raw Materials Price Trend 45

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 46

10.1. Manufacturing Cost Analysis 46

10.2. Manufacturing Process 46

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 47

11.1. Company Market Share Analysis – 2023 47

11.1.1. Africa Human Insulin Market: Company Market Share, by Volume, 2023 47

11.1.2. Africa Human Insulin Market: Company Market Share, by Revenue, 2023 48

11.1.3. Africa Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 48

11.1.4. Africa Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 49

11.2. Africa Human Insulin Market Company Volume Market Share, 2023 50

11.3. Africa Human Insulin Market Company Revenue Market Share, 2023 51

11.4. Company Assessment Metrics, 2023 52

11.4.1. Stars 52

11.4.2. Emerging Leaders 52

11.4.3. Pervasive Players 52

11.4.4. Participants 52

11.5. Start-ups /SMEs Assessment Metrics, 2023 52

11.5.1. Progressive Companies 52

11.5.2. Responsive Companies 52

11.5.3. Dynamic Companies 52

11.5.4. Starting Blocks 52

11.6. Strategic Developments 53

11.6.1. Acquisitions & Mergers 53

New Product Launch 53

Regional Expansion 53

11.7. Key Players Product Matrix 54

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 55

12.1. PESTEL 55

12.1.1. Political Factors 55

12.1.2. Economic Factors 55

12.1.3. Social Factors 55

12.1.4. Technological Factors 55

12.1.5. Environmental Factors 55

12.1.6. Legal Factors 55

12.2. Adjacent Market Analysis 55

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY DEVICE SEGMENT ANALYSIS 56

13.1. Human Insulin Market Overview, by Device Segment 56

13.1.1. Human Insulin Market Revenue Share, By Device, 2023 & 2032 57

13.1.2. Human Insulin Market Attractiveness Analysis, By Device 58

13.1.3. Incremental Revenue Growth Opportunity, by Device, 2024 – 2032 58

13.1.4. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 59

13.2. Pens 60

13.2.1. Africa Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61

13.2.2. Africa Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61

13.3. Syringes 62

13.3.1. Africa Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63

13.3.2. Africa Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63

13.4. Others 64

13.4.1. Africa Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65

13.4.2. Africa Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65

13.5. Device 4 66

13.5.1. Africa Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67

13.5.2. Africa Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67

13.6. Device 5 68

13.6.1. Africa Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69

13.6.2. Africa Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY INDICATION SEGMENT ANALYSIS 70

14.1. Human Insulin Market Overview, by Indication Segment 70

14.1.1. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 71

14.1.2. Human Insulin Market Attractiveness Analysis, By Indication 72

14.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 72

14.1.4. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 73

14.2. Type 1 Diabetes 74

14.2.1. Africa Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75

14.2.2. Africa Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75

14.3. Type 2 Diabetes 76

14.3.1. Africa Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77

14.3.2. Africa Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77

14.4. Gestational Diabetes 78

14.4.1. Africa Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79

14.4.2. Africa Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79

14.5. Indication 4 80

14.5.1. Africa Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81

14.5.2. Africa Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81

14.6. Indication 5 82

14.6.1. Africa Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83

14.6.2. Africa Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY INSULIN SEGMENT ANALYSIS 84

15.1. Human Insulin Market Overview, by Insulin Segment 84

15.1.1. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 85

15.1.2. Human Insulin Market Attractiveness Analysis, By Insulin 86

15.1.3. Incremental Revenue Growth Opportunity, by Insulin, 2024 – 2032 86

15.1.4. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 87

15.2. Rapid-acting insulin 88

15.2.1. Africa Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89

15.2.2. Africa Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89

15.3. Short-acting insulin 90

15.3.1. Africa Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91

15.3.2. Africa Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91

15.4. Intermediate-acting insulin 92

15.4.1. Africa Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93

15.4.2. Africa Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93

15.5. Others 94

15.5.1. Africa Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95

15.5.2. Africa Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95

15.6. Insulin 5 96

15.6.1. Africa Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97

15.6.2. Africa Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 98

16.1. Human Insulin Market Overview, by Technology Segment 98

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 99

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 100

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 100

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 101

16.2. Technology 1 102

16.2.1. Africa Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103

16.2.2. Africa Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103

16.3. Technology 2 104

16.3.1. Africa Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105

16.3.2. Africa Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105

16.4. Technology 3 106

16.4.1. Africa Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107

16.4.2. Africa Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107

16.5. Technology 4 108

16.5.1. Africa Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109

16.5.2. Africa Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109

16.6. Technology 5 110

16.6.1. Africa Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111

16.6.2. Africa Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111

CHAPTER NO. 17 : HUMAN INSULIN MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 112

17.1. Human Insulin Market Overview, by Distribution Channel Segment 112

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 113

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 114

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 114

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 115

17.2. Hospital Pharmacies 116

17.2.1. Africa Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117

17.2.2. Africa Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117

17.3. Drug Stores and Retail Pharmacies 118

17.3.1. Africa Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119

17.3.2. Africa Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119

17.4. Online Providers 120

17.4.1. Africa Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121

17.4.2. Africa Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121

17.5. Distribution Channel 4 122

17.5.1. Africa Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123

17.5.2. Africa Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123

17.6. Distribution Channel 5 124

17.6.1. Africa Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125

17.6.2. Africa Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125

CHAPTER NO. 18 : HUMAN INSULIN MARKET – REGIONAL ANALYSIS 126

18.1. Human Insulin Market Overview, by Regional Segments 126

18.2. Region 127

18.2.1. Africa Human Insulin Market Revenue Share, By Region, 2023 & 2032 127

18.2.2. Human Insulin Market Attractiveness Analysis, By Region 128

18.2.3. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 128

18.2.4. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 129

18.2.5. Africa Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130

18.2.6. Africa Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130

18.3. Device 131

18.3.1. Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131

18.4. Africa Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131

18.5. Indication 132

18.5.1. Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132

18.5.2. Africa Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132

18.6. Insulin 133

18.6.1. Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133

18.6.2. Africa Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133

18.7. Technology 134

18.7.1. Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134

18.7.2. Africa Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134

18.8. Distribution Channel 135

18.8.1. Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135

18.8.2. Africa Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135

CHAPTER NO. 19 : HUMAN INSULIN MARKET – NORTH AMERICA 136

19.1. North America 136

19.1.1. Key Highlights 136

19.1.2. North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137

19.1.3. North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138

19.1.4. North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139

19.1.5. North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140

19.1.6. North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141

19.1.7. North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142

19.2. U.S. 143

19.3. Canada 143

19.4. Mexico 143

CHAPTER NO. 20 : HUMAN INSULIN MARKET – EUROPE 144

20.1. Europe 144

20.1.1. Key Highlights 144

20.1.2. Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145

20.1.3. Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146

20.1.4. Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147

20.1.5. Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148

20.1.6. Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149

20.1.7. Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150

20.2. UK 151

20.3. France 151

20.4. Germany 151

20.5. Italy 151

20.6. Spain 151

20.7. Russia 151

20.8. Belgium 151

20.9. Netherland 151

20.10. Austria 151

20.11. Sweden 151

20.12. Poland 151

20.13. Denmark 151

20.14. Switzerland 151

20.15. Rest of Europe 151

CHAPTER NO. 21 : HUMAN INSULIN MARKET – ASIA PACIFIC 152

21.1. Asia Pacific 152

21.1.1. Key Highlights 152

21.1.2. Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153

21.1.3. Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154

21.1.4. Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155

21.1.5. Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156

21.1.6. Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157

21.1.7. Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158

21.2. China 159

21.3. Japan 159

21.4. South Korea 159

21.5. India 159

21.6. Australia 159

21.7. Thailand 159

21.8. Indonesia 159

21.9. Vietnam 159

21.10. Malaysia 159

21.11. Philippines 159

21.12. Taiwan 159

21.13. Rest of Asia Pacific 159

CHAPTER NO. 22 : HUMAN INSULIN MARKET – LATIN AMERICA 160

22.1. Latin America 160

22.1.1. Key Highlights 160

22.1.2. Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161

22.1.3. Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162

22.1.4. Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163

22.1.5. Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164

22.1.6. Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165

22.1.7. Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166

22.2. Brazil 167

22.3. Argentina 167

22.4. Peru 167

22.5. Chile 167

22.6. Colombia 167

22.7. Rest of Latin America 167

CHAPTER NO. 23 : HUMAN INSULIN MARKET – MIDDLE EAST 168

23.1. Middle East 168

23.1.1. Key Highlights 168

23.1.2. Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169

23.1.3. Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170

23.1.4. Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171

23.1.5. Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172

23.1.6. Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173

23.1.7. Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174

23.2. UAE 175

23.3. KSA 175

23.4. Israel 175

23.5. Turkey 175

23.6. Iran 175

23.7. Rest of Middle East 175

CHAPTER NO. 24 : HUMAN INSULIN MARKET – AFRICA 176

24.1. Africa 176

24.1.1. Key Highlights 176

24.1.2. Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177

24.1.3. Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178

24.1.4. Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179

24.1.5. Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180

24.1.6. Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181

24.1.7. Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182

24.2. Egypt 183

24.3. Nigeria 183

24.4. Algeria 183

24.5. Morocco 183

24.6. Rest of Africa 183

CHAPTER NO. 25 : COMPANY PROFILES 184

25.1. Novo Nordisk A/S 184

25.1.1. Company Overview 184

25.1.2. Product Portfolio 184

25.1.3. Swot Analysis 184

25.1.4. Business Strategy 185

25.1.5. Financial Overview 185

25.1.6. MannKind Corporation 186

25.1.7. Pfizer 186

25.1.8. Wockhardt 186

25.1.9. Biocon 186

25.1.10. Lupin 186

25.1.11. Tonghua Dongbao Pharmaceutical Co 186

25.1.12. Eli Lilly and Company 186

25.1.13. Company 9 186

25.1.14. Company 10 186

25.1.15. Company 11 186

25.1.16. Company 12 186

25.1.17. Company 13 186

25.1.18. Company 14 186

CHAPTER NO. 26 : RESEARCH METHODOLOGY 187

26.1. Research Methodology 187

26.1.1. Phase I – Secondary Research 188

26.1.2. Phase II – Data Modeling 188

Company Share Analysis Model 189

Revenue Based Modeling 189

26.1.3. Phase III – Primary Research 190

26.1.4. Research Limitations 191

Assumptions 191

List of Figures

FIG NO. 1. Africa Human Insulin Market Revenue, 2018 – 2032 (USD Million) 30

FIG NO. 2. Porter’s Five Forces Analysis for Africa Human Insulin Market 37

FIG NO. 3. Value Chain Analysis for Africa Human Insulin Market 38

FIG NO. 4. Africa Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 40

FIG NO. 5. Africa Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 41

FIG NO. 6. Africa Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 42

FIG NO. 7. Africa Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 43

FIG NO. 8. Africa Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 44

FIG NO. 9. Africa Human Insulin Market Price, By Region, 2018 – 2023 45

FIG NO. 10. Africa Human Insulin Market Price, By Device, 2018 – 2023 46

FIG NO. 11. Raw Materials Price Trend Analysis, 2018 – 2023 47

FIG NO. 12. Manufacturing Cost Analysis 48

FIG NO. 13. Manufacturing Process 48

FIG NO. 14. Company Share Analysis, 2023 49

FIG NO. 15. Company Share Analysis, 2023 50

FIG NO. 16. Company Share Analysis, 2023 50

FIG NO. 17. Company Share Analysis, 2023 51

FIG NO. 18. Human Insulin Market – Company Volume Market Share, 2023 52

FIG NO. 19. Human Insulin Market – Company Revenue Market Share, 2023 53

FIG NO. 20. Human Insulin Market Revenue Share, By Device, 2023 & 2032 59

FIG NO. 21. Market Attractiveness Analysis, By Device 60

FIG NO. 22. Incremental Revenue Growth Opportunity by Device, 2024 – 2032 60

FIG NO. 23. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 61

FIG NO. 24. Africa Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 62

FIG NO. 25. Africa Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 26. Africa Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 66

FIG NO. 27. Africa Human Insulin Market for Device 4, Revenue (USD Million) 2018 – 2032 68

FIG NO. 28. Africa Human Insulin Market for Device 5, Revenue (USD Million) 2018 – 2032 70

FIG NO. 29. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 73

FIG NO. 30. Market Attractiveness Analysis, By Indication 74

FIG NO. 31. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 74

FIG NO. 32. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 75

FIG NO. 33. Africa Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 76

FIG NO. 34. Africa Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 78

FIG NO. 35. Africa Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 80

FIG NO. 36. Africa Human Insulin Market for Indication 4, Revenue (USD Million) 2018 – 2032 82

FIG NO. 37. Africa Human Insulin Market for Indication 5, Revenue (USD Million) 2018 – 2032 84

FIG NO. 38. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 87

FIG NO. 39. Market Attractiveness Analysis, By Insulin 88

FIG NO. 40. Incremental Revenue Growth Opportunity by Insulin, 2024 – 2032 88

FIG NO. 41. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 89

FIG NO. 42. Africa Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 90

FIG NO. 43. Africa Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 92

FIG NO. 44. Africa Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 94

FIG NO. 45. Africa Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 96

FIG NO. 46. Africa Human Insulin Market for Insulin 5, Revenue (USD Million) 2018 – 2032 98

FIG NO. 47. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 101

FIG NO. 48. Market Attractiveness Analysis, By Technology 102

FIG NO. 49. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 102

FIG NO. 50. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 103

FIG NO. 51. Africa Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 104

FIG NO. 52. Africa Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 106

FIG NO. 53. Africa Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 108

FIG NO. 54. Africa Human Insulin Market for Technology 4, Revenue (USD Million) 2018 – 2032 110

FIG NO. 55. Africa Human Insulin Market for Technology 5, Revenue (USD Million) 2018 – 2032 112

FIG NO. 56. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 115

FIG NO. 57. Market Attractiveness Analysis, By Distribution Channel 116

FIG NO. 58. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 116

FIG NO. 59. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 117

FIG NO. 60. Africa Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 118

FIG NO. 61. Africa Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 120

FIG NO. 62. Africa Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 122

FIG NO. 63. Africa Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 124

FIG NO. 64. Africa Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 126

FIG NO. 65. Africa Human Insulin Market Revenue Share, By Region, 2023 & 2032 129

FIG NO. 66. Market Attractiveness Analysis, By Region 130

FIG NO. 67. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 130

FIG NO. 68. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 131

FIG NO. 69. North America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 138

FIG NO. 70. Europe Human Insulin Market Revenue, 2018 – 2032 (USD Million) 146

FIG NO. 71. Asia Pacific Human Insulin Market Revenue, 2018 – 2032 (USD Million) 154

FIG NO. 72. Latin America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 162

FIG NO. 73. Middle East Human Insulin Market Revenue, 2018 – 2032 (USD Million) 170

FIG NO. 74. Africa Human Insulin Market Revenue, 2018 – 2032 (USD Million) 178

FIG NO. 75. Research Methodology – Detailed View 189

FIG NO. 76. Research Methodology 190

List of Tables

TABLE NO. 1. : Africa Human Insulin Market: Snapshot 27

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 31

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 33

TABLE NO. 4. : Africa Human Insulin Market Revenue, By Region, 2018 – 2023 43

TABLE NO. 5. : Africa Human Insulin Market Revenue, By Device, 2018 – 2023 44

TABLE NO. 6. : Key Raw Materials & Suppliers 45

TABLE NO. 7. : Africa Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61

TABLE NO. 8. : Africa Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61

TABLE NO. 9. : Africa Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63

TABLE NO. 10. : Africa Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63

TABLE NO. 11. : Africa Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65

TABLE NO. 12. : Africa Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65

TABLE NO. 13. : Africa Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67

TABLE NO. 14. : Africa Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67

TABLE NO. 15. : Africa Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69

TABLE NO. 16. : Africa Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69

TABLE NO. 17. : Africa Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75

TABLE NO. 18. : Africa Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75

TABLE NO. 19. : Africa Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77

TABLE NO. 20. : Africa Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77

TABLE NO. 21. : Africa Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79

TABLE NO. 22. : Africa Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79

TABLE NO. 23. : Africa Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81

TABLE NO. 24. : Africa Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81

TABLE NO. 25. : Africa Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83

TABLE NO. 26. : Africa Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83

TABLE NO. 27. : Africa Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89

TABLE NO. 28. : Africa Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89

TABLE NO. 29. : Africa Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91

TABLE NO. 30. : Africa Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91

TABLE NO. 31. : Africa Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93

TABLE NO. 32. : Africa Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93

TABLE NO. 33. : Africa Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95

TABLE NO. 34. : Africa Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95

TABLE NO. 35. : Africa Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97

TABLE NO. 36. : Africa Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97

TABLE NO. 37. : Africa Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103

TABLE NO. 38. : Africa Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103

TABLE NO. 39. : Africa Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105

TABLE NO. 40. : Africa Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105

TABLE NO. 41. : Africa Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107

TABLE NO. 42. : Africa Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107

TABLE NO. 43. : Africa Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109

TABLE NO. 44. : Africa Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109

TABLE NO. 45. : Africa Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111

TABLE NO. 46. : Africa Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111

TABLE NO. 47. : Africa Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117

TABLE NO. 48. : Africa Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117

TABLE NO. 49. : Africa Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119

TABLE NO. 50. : Africa Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119

TABLE NO. 51. : Africa Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121

TABLE NO. 52. : Africa Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121

TABLE NO. 53. : Africa Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123

TABLE NO. 54. : Africa Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123

TABLE NO. 55. : Africa Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125

TABLE NO. 56. : Africa Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125

TABLE NO. 57. : Africa Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130

TABLE NO. 58. : Africa Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130

TABLE NO. 59. : Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131

TABLE NO. 60. : Africa Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131

TABLE NO. 61. : Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132

TABLE NO. 62. : Africa Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132

TABLE NO. 63. : Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133

TABLE NO. 64. : Africa Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133

TABLE NO. 65. : Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134

TABLE NO. 66. : Africa Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134

TABLE NO. 67. : Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135

TABLE NO. 68. : Africa Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135

TABLE NO. 69. : North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137

TABLE NO. 70. : North America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 137

TABLE NO. 71. : North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138

TABLE NO. 72. : North America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 138

TABLE NO. 73. : North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139

TABLE NO. 74. : North America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 139

TABLE NO. 75. : North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140

TABLE NO. 76. : North America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 140

TABLE NO. 77. : North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141

TABLE NO. 78. : North America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 141

TABLE NO. 79. : North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142

TABLE NO. 80. : North America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 142

TABLE NO. 81. : Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145

TABLE NO. 82. : Europe Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 145

TABLE NO. 83. : Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146

TABLE NO. 84. : Europe Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 146

TABLE NO. 85. : Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147

TABLE NO. 86. : Europe Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 147

TABLE NO. 87. : Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148

TABLE NO. 88. : Europe Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 148

TABLE NO. 89. : Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149

TABLE NO. 90. : Europe Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 149

TABLE NO. 91. : Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150

TABLE NO. 92. : Europe Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 150

TABLE NO. 93. : Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153

TABLE NO. 94. : Asia Pacific Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 153

TABLE NO. 95. : Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154

TABLE NO. 96. : Asia Pacific Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 154

TABLE NO. 97. : Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155

TABLE NO. 98. : Asia Pacific Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 155

TABLE NO. 99. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156

TABLE NO. 100. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 156

TABLE NO. 101. : Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157

TABLE NO. 102. : Asia Pacific Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 157

TABLE NO. 103. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158

TABLE NO. 104. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 158

TABLE NO. 105. : Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161

TABLE NO. 106. : Latin America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 161

TABLE NO. 107. : Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162

TABLE NO. 108. : Latin America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 162

TABLE NO. 109. : Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163

TABLE NO. 110. : Latin America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 163

TABLE NO. 111. : Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164

TABLE NO. 112. : Latin America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 164

TABLE NO. 113. : Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165

TABLE NO. 114. : Latin America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 165

TABLE NO. 115. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166

TABLE NO. 116. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 166

TABLE NO. 117. : Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169

TABLE NO. 118. : Middle East Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 169

TABLE NO. 119. : Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170

TABLE NO. 120. : Middle East Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 170

TABLE NO. 121. : Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171

TABLE NO. 122. : Middle East Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 171

TABLE NO. 123. : Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172

TABLE NO. 124. : Middle East Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 172

TABLE NO. 125. : Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173

TABLE NO. 126. : Middle East Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 173

TABLE NO. 127. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174

TABLE NO. 128. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 174

TABLE NO. 129. : Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177

TABLE NO. 130. : Africa Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 177

TABLE NO. 131. : Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178

TABLE NO. 132. : Africa Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 178

TABLE NO. 133. : Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179

TABLE NO. 134. : Africa Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 179

TABLE NO. 135. : Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180

TABLE NO. 136. : Africa Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 180

TABLE NO. 137. : Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181

TABLE NO. 138. : Africa Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 181

TABLE NO. 139. : Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182

TABLE NO. 140. : Africa Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 182

Frequently Asked Questions

What is the current size of the Africa Human Insulin?

The Africa human insulin market was valued at USD 383.25 million in 2023 and is projected to reach USD 415.07 million by 2032.

What factors are driving the growth of the Africa Human Insulin?

Growth is driven by the rising prevalence of diabetes, government healthcare initiatives, and improved insulin production and delivery technologies.

What are some challenges faced by the Africa Human Insulin?

Challenges include high insulin costs, limited healthcare infrastructure, and restricted access in rural and underserved regions.

Who are the major players in the Africa Human Insulin?

Key players include Novo Nordisk, Eli Lilly, Pfizer, Biocon, MannKind, Wockhardt, Lupin, and Tonghua Dongbao Pharmaceutical Co.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –